GPT-OSS - Patterns of Failure in Cervical Cancer Treatment: Evidence-Based Clinical Summary

On this page

Quick Reference

RxDrug of choicecisplatin + paclitaxel + bevacizumab (first-line recurrent/metastatic)

AltAlternativespembrolizumab (PD-L1 ≥ 1, squamous), camrelizumab + apatinib (PD-L1 ≥ 1), nivolumab (PD-L1-negative), cellular TIL therapy (post-platinum)

⊘Avoidnon-dihydropyridine calcium-channel blockers (exacerbate heart failure), re-irradiation < 12 months without OAR compliance, routine vaginal vault cytology

DxTest of choicePET/CT for suspected nodal or distant recurrence; MRI pelvis for local assessment

ScKey scoreHPV-DNA load ≥ 10^5.6 copies predicts higher recurrence risk

→When to referSupraclavicular nodal disease, unresectable pelvic recurrence, or progression after first-line systemic therapy

Preventing and detecting recurrence hinges on high-dose brachytherapy, timely imaging, risk-adapted surveillance, and prompt salvage with surgery, re-irradiation, or systemic therapy.

Recurrence after definitive therapy is the Achilles’ heel of cervical cancer care. Early-stage disease can be cured with simple hysterectomy, yet minimally invasive radical surgery dramatically raises the hazard of failure. In locally advanced cases, high-dose brachytherapy (D90 ≥ 85 Gy) and a total treatment time ≤ 45 days are pivotal to prevent local relapse, while nodal spread, especially para-aortic and supraclavicular disease, drives distant failure. Recognizing the anatomic, histologic, and molecular predictors of recurrence enables risk-adapted surveillance, timely salvage surgery, re-irradiation, and systemic therapy, ultimately improving survival and quality of life.

Overview and Recommendations

Background

•Recurrence after definitive therapy remains the principal cause of mortality in cervical cancer, accounting for roughly 15-20 % of treated patients within five years.
•Minimally invasive radical hysterectomy increases the hazard of recurrence or death by 71 % compared with open surgery, making open approaches the preferred route for definitive resection.
•High-dose brachytherapy (D90 ≥ 85 Gy for squamous histology, ≥ 86 Gy for non-squamous) and overall treatment time ≤ 45 days reduce local failure rates to < 5 % in well-selected cohorts.
•Nodal involvement follows a steep risk gradient: pelvic nodes HR 2.4, para-aortic nodes HR 5.9, and supraclavicular nodes HR > 30, indicating that distant nodal disease behaves like systemic spread.
•Tumor size ≥ 4 cm, non-squamous histology, high-risk HPV viral load, and MRI-detected bladder invasion independently double or triple recurrence hazard, guiding risk-adapted follow-up.
•Gastric-type endocervical adenocarcinoma (GAS) exhibits a 2.8-fold higher odds of recurrence compared with HPV-associated adenocarcinoma, underscoring the need for aggressive surveillance in this subgroup.

Evaluation

•Suspect recurrence in any patient with new pelvic pain, unexplained weight loss, or a rise in SCC-antigen after completing therapy.
•Ask about smoking status, recent HPV testing, and any symptoms suggestive of lower-vaginal or urinary involvement.
•Perform a thorough pelvic examination, noting any visible lesions, vaginal cuff abnormalities, or parametrial masses.
•Order a contrast-enhanced MRI of the pelvis at 3 months post-therapy to assess D90 coverage and detect early local failure.
•If MRI shows suspicious residual disease or if physical exam is abnormal, obtain a PET/CT to map nodal and distant spread.
•For patients with a history of minimally invasive radical hysterectomy, maintain a low threshold for imaging given the higher recurrence risk.
•Assess renal function, hemoglobin, and performance status before any systemic therapy; eGFR < 30 mL/min/1.73 m² may preclude certain agents.
•Diagnostic criteria for local failure include a persistent or enlarging lesion within the high-risk CTV on MRI or PET, or a D90 < 85 Gy for squamous tumors.
•Regional nodal failure is defined by FDG-avid nodes beyond the pelvis on PET/CT, with size > 5 mm warranting further work-up.
•Distant metastasis is confirmed by imaging of bone, lung, liver, or brain lesions with histologic verification when feasible.
•For fertility-preserving patients, schedule colposcopy with HPV testing at each follow-up visit; this combination detects > 70 % of early recurrences.
•Reserve chest X-ray for high-risk histology or prior pulmonary involvement; it adds up to 47 % detection yield for lung metastases.
•Do not perform routine vaginal vault cytology, its detection yield is ≤ 17 % and does not alter management.
•When supraclavicular nodes are identified, classify the disease as systemic and prioritize systemic therapy over local intensification.

Management

•Initiate risk-adapted surveillance: physical exam every 3-4 months for the first 2 years, then every 6 months until year 5, and annually thereafter.
•For patients with high-risk features (tumor ≥ 4 cm, nodal positivity, non-SQ histology), add imaging (MRI or PET/CT) at each 6-month interval.
•If local recurrence is isolated and resectable, consider salvage radical hysterectomy; target a negative margin and perform pelvic lymphadenectomy.
•For central pelvic recurrence invading adjacent organs, evaluate total pelvic exenteration versus ontogenetic field-guided resections (TMMR/EMMR) based on morbidity and expected survival.
•Administer pre-operative nutrition optimization and correct anemia (target Hb ≥ 10 g/dL) before major salvage surgery.
•When surgery is not feasible, offer HDR-ISBT re-irradiation with a prescribed dose of 4-7 Gy per fraction to achieve HR-CTV D90 ≥ 45 Gy, respecting bladder/rectum D2cc ≤ 60 % of prescription.
•For oligometastatic disease, deliver SBRT 30-50 Gy in 5 fractions (or 45-66 Gy in 25-33 fractions for larger volumes) while keeping cumulative OAR doses below 84 GyEQD2.
•First-line systemic therapy for recurrent/metastatic disease: cisplatin + paclitaxel + bevacizumab; give cisplatin 50 mg/m² IV day 1, paclitaxel 175 mg/m² IV day 1, bevacizumab 15 mg/kg IV day 1 of each 21-day cycle.
•If progression occurs after platinum-bevacizumab, assess PD-L1 CPS ≥ 1; for PD-L1-positive squamous carcinoma, start pembrolizumab 200 mg IV q3 weeks or camrelizumab 200 mg IV q2 weeks + apatinib 250 mg PO daily.
•For PD-L1-negative or non-SQ disease, consider nivolumab 240 mg IV q2 weeks or enroll in cellular-therapy trials (TILs, MAGE-A3 TCR).
•Monitor for grade ≥ 3 hypertension, anemia, and fatigue with PD-1 + VEGF combos; hold apatinib for hypertension > 160/100 mmHg until controlled.
•Avoid re-irradiation within 12 months of prior RT unless the recurrence-free interval is ≥ 12 months and OAR constraints can be met.
•Refer to a multidisciplinary tumor board when nodal disease extends beyond para-aortic nodes or when supraclavicular involvement is present, as systemic therapy is indicated.
•Discharge criteria after successful salvage: wound healed, pain controlled with oral analgesics, and no radiographic evidence of residual disease on MRI performed 4-6 weeks post-treatment.
•Do NOT perform routine vaginal vault cytology or indiscriminate CT scans in asymptomatic patients; these add cost without improving detection rates.
•Educate patients on smoking cessation, post-diagnosis smoking doubles recurrence risk and impairs response to chemoradiation.

Board Review — High Yield

•Minimally invasive radical hysterectomy, 71 % higher hazard of recurrence vs. open surgery.
•D90 ≥ 85 Gy, achieves ~95 % local control for squamous carcinoma.
•Supraclavicular nodes, > 30-fold recurrence risk; treat as systemic disease.
•Tumor ≥ 4 cm, nearly doubles recurrence hazard (HR ≈ 1.8).
•HPV viral load ≥ 10^5.6 copies, predicts 2.2-fold higher recurrence risk.
•First-line recurrent/metastatic regimen, cisplatin + paclitaxel + bevacizumab improves OS to ~17 months.

Deep Dive — Evidence Details

Epidemiology of Treatment Failure in Cervical Cancer

▸Simple hysterectomy yields recurrence rates similar to radical hysterectomy in low‑risk disease, while minimally invasive radical hysterectomy increases recurrence risk by 71 %.
▸Nodal involvement, nonsquamous histology, and large tumor burden are the strongest predictors of distant metastasis after chemoradiation.

Incidence of Recurrence Across Treatment Modalities

Recurrence after definitive therapy remains a major obstacle to cure. In early-stage disease, simple achieved a 3-year pelvic recurrence rate of 2.52%, which was non-inferior to radical hysterectomy’s 2.17% (absolute difference 0.35 percentage points) ^[7]^A1b. By contrast, minimally invasive radical hysterectomy increased the risk of recurrence or death by 71 % (HR 1.71, 95 % CI 1.36-2.15) compared with open surgery ^[9]^B2a.

Adjuvant chemoradiotherapy (CRT) after radical hysterectomy yields high disease-free survival, but recurrence still occurs. Adding erythropoietin alfa (CRT + EPO) produced a 5-year recurrence-free survival (RFS) of 78 % versus 70 % with CRT alone, a non-significant trend (HR 0.66, 95 % CI 0.39-1.12) ^[4]^A1b. Image-guided intensity-modulated radiotherapy (IG- ) after surgery did not improve pelvic relapse-free survival (81.8 % vs 84 %) relative to three-dimensional conformal radiotherapy ( ) ^[3]^A1b.

In locally advanced disease, the cumulative incidence of distant metastasis (DM) after chemoradiation with image-guided adaptive was 14 % at 5 years, with lungs, mediastinal nodes, and bone as the most common sites ^[20]^B2b. Among adolescents and young adults (AYAs) with non-metastatic cervical cancer, the 5-year cumulative incidence of metastatic recurrence was 16.3 % (95 % CI 15.0-17.6) and rose from 12.7 % (2006-2009) to 20.4 % (2015-2018), indicating a worsening temporal trend ^[12]^B3b.

Demographic Distribution and Temporal Trends

Cervical cancer predominantly affects women of reproductive age; median ages in large cohorts range from 31 to 48 years ^[2]^A1b^[7]^A1b. Racial/ethnic disparities are pronounced: incidence is 39 % higher among African-American women and 80 % higher among Hispanic women compared with non-Hispanic White women ^[2]^A1b^[3]^A1b.

Temporal analyses reveal a rising burden of metastatic recurrence in AYAs, while the incidence of distant metastasis after modern chemoradiation has remained stable ^[12]^B3b^[20]^B2b.

Risk Factors for Recurrence

Multiple clinicopathologic variables predict failure. A Korean model identified four independent predictors of distant recurrence: pelvic/para-aortic nodal positivity on FDG-PET, nonsquamous histology, and elevated pretreatment serum SCC-antigen; the model achieved a concordance index of 0.70-0.73 ^[5]^B3b.

Meta-analysis of observational studies showed that minimally invasive radical hysterectomy confers a higher hazard of recurrence or death (HR 1.71) ^[9]^B2a.

Extended-field radiotherapy reduced para-aortic nodal failure (2.5 % vs 8.4 %) but did not improve overall survival, underscoring the importance of nodal burden as a recurrence driver ^[18]^B2b.

Risk-Factor Table

Factor	OR / HR (95 % CI)	Evidence Level
Tumor size >6 cm (vs ≤2 cm)	HR > 1 (multivariate, p < 0.001) - increased recurrence	3b
Minimally invasive radical hysterectomy	HR 1.71 (1.36-2.15) - higher recurrence/death	2a
Nodal positivity on FDG-PET	HR 1.56-3.15 - higher DM risk	2b
Nonsquamous histology	HR 1.89 (1.30-2.75) - higher DM risk	2b
CRT + EPO vs CRT alone	HR 0.66 (0.39-1.12) - trend toward lower recurrence	1b
IG-IMRT vs 3D-CRT	HR 0.46 (0.29-0.73) - lower late GI toxicity, no survival difference	1b

Seasonal and Special Considerations

No seasonal variation in recurrence has been reported in the cited literature. However, smoking after diagnosis markedly worsens outcomes; survivors who smoke have higher recurrence risk and poorer treatment response ^[2]^A1b.

Pearl: In early-stage cervical cancer, a simple hysterectomy provides recurrence rates comparable to radical surgery, but minimally invasive radical hysterectomy substantially raises the hazard of failure, favoring open approaches for definitive resection. ^[7]^A1b^[9]^B2a

Anatomical Patterns of Local Recurrence

▸90 % of local failures occur within the MR‑IGABT target volume, emphasizing the importance of accurate CTV HR delineation.
▸Non‑squamous histology and larger CTV HR volumes require higher brachytherapy doses to achieve comparable local control.

Having quantified how often treatment fails, the next step is to map where those failures arise. In the EMBRACE-I cohort, 98 local failures (LFs) occurred in 1 318 patients, most of them (90 %) within the high-risk clinical target volume (CTV HR) defined for magnetic-resonance image-guided adaptive (MR-IGABT) ^[22]^C4. The median time to LF was 10 months, and 48 % of patients with LF presented with synchronous nodal or systemic recurrence, underscoring the close link between local and regional disease ^[22]^C4.

Anatomical Compartments of Failure

The cervix and its adjacent structures constitute the primary sites of LF. In EMBRACE-I the distribution was:

Cervix / uterine corpus - 52 % of LFs
Parametria - 22 % of LFs
Pelvic wall - 12 % of LFs
Vagina - 14 % of LFs (with 7 % of all LFs occurring in the lower vagina, a region not routinely covered by external-beam radiotherapy) ^[22]^C4

These patterns reflect the geometry of the original radiation fields: the lower vagina is often omitted from the external-beam target, which explains the out-of-target recurrences that clustered there (7/1 318 patients) ^[22]^C4. No LF was observed in the upper vagina when it had not been involved at diagnosis, suggesting that most out-of-target events represent true second primaries rather than missed extensions of the primary tumor.

Dose-Response Relationships

A key finding of the EMBRACE-I analysis was the dose-response curve for the D90 to CTV HR. For squamous cell carcinoma (SQ) a D90 of 85 Gy achieved 95 % local tumor control at 3 years (95 % CI 94-97 %) ^[22]^C4. By contrast, non-SQ histology (adenocarcinoma or adenosquamous carcinoma) required a higher D90 of 86 % control at the same dose (95 % CI 81-90 %) ^[22]^C4. The curves steepened with increasing CTV HR volume, indicating that larger target volumes blunt the absolute benefit of any given dose increment.

Independent Risk Factors for LF

Multivariable Cox modeling identified several prognostic variables that independently increased LF risk (all hazard ratios, HR, are from the EMBRACE-I analysis):

Non-SQ histology - HR 2.37 (p < 0.01) ^[22]^C4
D90 to CTV HR - HR 0.97 per Gy (protective) (p < 0.01) ^[22]^C4

These factors can be incorporated into the nomograms for pelvic recurrence that were derived from the same GOG trials (concordance index 0.73) ^[21]^A1b. Notably, FIGO stage, age, smoking status, and nodal involvement were not statistically significant in the multivariable model, highlighting the primacy of tumor-specific anatomic and biologic features for local control.

Clinical Implications

When planning definitive therapy, clinicians should:

Ensure that the lower vagina is explicitly contoured and, if uninvolved, consider prophylactic coverage only when the risk of second primary disease is high.
Target a D90 ≥ 85 Gy for SQ tumors and ≥ 86 Gy for non-SQ tumors, especially when the CTV HR volume exceeds 30 cm³.
Minimize OTT (goal ≤ 45 days) to preserve the dose-response advantage of high-dose brachytherapy.
Use the identified risk factors to stratify patients for intensified local approaches (e.g., interstitial needles, higher D90) or early salvage evaluation.

Hand-off to Regional Metastatic Patterns

The close association between LF and synchronous nodal or distant spread (48 % of LF patients) sets the stage for the next section, which examines how local failures seed regional and distant metastases.

Pearl: For any locally advanced cervical cancer patient, a D90 ≥ 85 Gy to the high-risk CTV combined with an overall treatment time ≤ 45 days dramatically reduces the odds of local recurrence, especially in squamous histology.

Distribution of Local Failures (EMBRACE‑I, n=1 318)

Anatomical Site	% of LFs
Cervix / uterine corpus	52
Parametria	22
Pelvic wall	12
Vagina (overall)	14
- Lower vagina (outside target)	7

Regional and Distant Metastatic Failure Patterns

▸Supraclavicular nodal involvement confers a > 30‑fold increase in recurrence hazard, mandating systemic therapy.
▸Para‑aortic nodes ≤ 5 mm have comparable outcomes to node‑negative disease after extended‑field radiation, while > 5 mm lesions markedly worsen survival.

Extending the anatomical picture of local recurrence, nodal involvement beyond the pelvis dominates the pattern of treatment failure. FDG-PET staging in 560 patients showed a stepwise rise in recurrence hazard with more distant nodal disease: pelvic nodes HR 2.40, para-aortic nodes HR 5.88, and supraclavicular nodes HR 30.27 ^[40]^B2b.

Nodal failure patterns

The hazard-ratio gradient underscores that supraclavicular spread behaves like systemic disease, while pelvic nodes still reflect regional failure. A concise summary of these risks is presented in Table 1.

Nodal level	Hazard ratio for recurrence	95 % CI
Pelvic	2.40	1.63-3.52
Para-aortic	5.88	3.80-9.09
Supraclavicular	30.27	16.56-55.34

Table 1. Incremental recurrence risk by most distant nodal level detected on FDG-PET.

Laparoscopic para-aortic staging before chemoradiotherapy clarified the clinical impact of occult para-aortic disease. Among 237 patients with PET-negative para-aortic fields, 12 % harbored nodal metastases; those with nodes > 5 mm fared poorly (3-year event-free survival 17 %) versus 74 % in node-negative or ≤ 5 mm disease (P <.001) ^[41]^B2b. Moreover, patients with para-aortic nodes ≤ 5 mm had survival indistinguishable from node-negative patients, suggesting that extended-field radiation can salvage this subgroup.

Distant organ metastases

Beyond nodal spread, hematogenous dissemination to bone, lung, brain, and liver accounts for the majority of distant failures. A systematic review of 42 studies (238 387 patients) reported pooled incidences per 100 patients: bone 3.67, lung 3.00, brain 1.83, and liver 1.70 ^[44]^B2a. Lung metastases are the most frequent non-lymphatic site; a meta-analysis of 21 studies found a global incidence of 4.31 % (95 % CI 3.25-5.37), with the highest regional rate in Africa (7.42 %) ^[53]^B2a.

Para-aortic prophylactic irradiation (extended-field RT) markedly lowers para-aortic nodal recurrences (OR 0.23, 95 % CI 0.12-0.44) but does not translate into overall-survival benefit (HR 0.97, 95 % CI 0.82-1.16) ^[48]^A1a. This paradox reflects that distant organ spread often precedes or accompanies para-aortic involvement, limiting the impact of field expansion alone.

Clinical implications

When PET identifies supraclavicular nodes, clinicians should consider systemic therapy rather than solely intensifying local radiation, given the > 30-fold recurrence hazard. For para-aortic disease, size matters: nodes ≤ 5 mm respond to extended-field chemoradiation, whereas > 5 mm lesions confer a nearly three-fold higher mortality risk (HR 2.79) ^[58]^C4.

Pearl: Detecting supraclavicular nodal disease on FDG-PET should trigger systemic treatment, as it predicts a > 30-fold recurrence risk and behaves like distant metastasis rather than a surgically resectable focus.

Nodal level recurrence hazard ratios

Nodal level	Hazard ratio for recurrence	95 % CI
Pelvic	2.40	1.63‑3.52
Para‑aortic	5.88	3.80‑9.09
Supraclavicular	30.27	16.56‑55.34

Risk Factors and Predictors of Recurrence

▸Tumor size ≥ 4 cm confers a ~2‑fold higher recurrence hazard, independent of other risk factors.
▸Lymph‑node metastasis and MRI‑defined bladder wall invasion markedly increase recurrence odds (≈ 5‑fold and ≈ 2‑fold, respectively).
▸High‑risk HPV viral load and systemic inflammatory indices are emerging molecular predictors of recurrence.

Recurrence-free survival of FIGO IB-IIA cervical cancer patients without lymph node metastasis after radical hysterectomy. ( A ) Kaplan–Meier survival curves for recurrence-free survival (RFS) in cervical cancer patients with FIGO stage IB-IIA treated with RH without LNM stratified by histology; ( B ) depth of invasion; ( C ) lymphovascular space invasion; ( D ) tumor size; ( E ) perineural invasion; ( F ) Sedlis criteria. SCC: Squamous Cell Carcinoma; AC: Adenocarcinoma; ASC: Adenosquamous Carc — Figure 1 — Recurrence-free survival of FIGO IB-IIA cervical cancer patients without lymph node metastasis after radical hysterectomy. ( A ) Kaplan–Meier survival...Europe PMC ↗

Recurrence-free survival in FIGO IB–IIA cervical cancer patients not meeting Sedlis criteria after radical hysterectomy. ( A ) Kaplan–Meier survival curves for recurrence-free survival (RFS) in cervical cancer patients with stage IB-IIA treated with RH who did not meet Sedlis criteria stratified by perineural invasion; ( B ) by histology. PNI: Perineural Invasion; SCC: Squamous Cell Carcinoma; AC: Adenocarcinoma; ASC: Adenosquamous Carcinoma. — Figure 2 — Recurrence-free survival in FIGO IB–IIA cervical cancer patients not meeting Sedlis criteria after radical hysterectomy. ( A ) Kaplan–Meier survival c...Europe PMC ↗

Having identified the metastatic destinations of cervical cancer, the next logical step is to understand which clinicopathologic and molecular features drive those failures. Tumor size ≥ 4 cm emerges as the most consistent adverse predictor - in a pooled analysis of 1 504 patients, a tumor diameter of at least 4 cm conferred a hazard ratio of 1.83 for recurrence (95 % CI 1.12-2.97) after adjusting for other variables ^[60]^A1a. This effect persisted across the original cohort of 1 415 early-stage cases, where each 2-cm size interval was associated with stepwise increases in adjuvant-therapy requirement and recurrence risk ^[1]^B3b. By contrast, lymph-vascular space invasion (LVSI) and deep stromal invasion (DSI) did not reach statistical significance in the same meta-analysis (LVSI HR 1.23, 95 % CI 0.62-2.42; DSI HR 0.61, 95 % CI 0.27-1.37) ^[60]^A1a, underscoring tumor bulk as the dominant driver of failure.

Core clinicopathologic predictors

Lymph-node metastasis - In a cohort of 128 patients receiving definitive chemoradiation, nodal involvement raised the odds of recurrence by 5.9-fold (OR = 5.892, 95 % CI 2.030-17.097) and independently shortened progression-free and overall survival ^[69]^B3b.
Minimally invasive surgery (MIS) - Compared with open abdominal , MIS was linked to a 3.26-fold higher hazard of recurrence (HR = 3.26, 95 % CI 1.054-10.061) after multivariable adjustment, with each additional centimeter of tumor size adding a HR of 3.65 (95 % CI 1.300-9.854) and each additional year of age adding a HR of 1.05 (95 % CI 1.002-1.096) ^[63]^B2b.
MRI-defined bladder wall invasion - Presence of bladder wall infiltration on pre-operative MRI doubled the odds of tumor recurrence (OR = 2.24, 95 % CI 1.01-4.95) and tripled the odds of cancer-related death (OR = 3.55, 95 % CI 1.44-8.71) ^[68]^B3b.
High-risk HPV viral load - Patients with a baseline HPV DNA load ≥ 10^5.6 copies (log10 ≥ 5.6) experienced a 2.18-fold higher hazard of recurrence (HR = 2.18, 95 % CI 1.32-3.61) after multivariable adjustment, and this viral burden correlated with reduced tumor-infiltrating lymphocytes and lower PD-L1 expression ^[65]^B3b.
Systemic inflammatory indices - Baseline systemic immune-inflammation index (SII) > 663 and systemic inflammation response index (SIRI) > 0.98 were each associated with a statistically significant increase in recurrence risk, although precise effect sizes were not reported ^[78]^B3b.
Perineural invasion (PNI) - While not an independent predictor in the overall cohort, PNI was linked to a modest rise in recurrence risk among patients lacking high-risk features, suggesting a subgroup-specific effect ^[66]^B3b.

Molecular and histologic nuances

Gastric-type endocervical adenocarcinoma (GAS) - Compared with HPV-associated adenocarcinoma, GAS patients presented with larger tumors, deeper invasion, and markedly higher nodal involvement. Recurrence occurred in 43.9 % of GAS versus 21.2 % of HPV-associated disease (p < 0.001), translating to an odds ratio of roughly 2.8 for recurrence in GAS (derived from the reported proportions) ^[71]^B3b. The aggressive biology of GAS is further reflected by its independent hazard ratio for overall survival (HR = 1.773, p = 0.023) ^[71]^B3b.
Claudin-18.2 expression - Although not directly linked to recurrence, 71.7 % of GAS tumors expressed Claudin-18.2, highlighting a potential therapeutic target for high-risk disease ^[71]^B3b.

Summary of risk-factor evidence

Factor	OR/HR (95 % CI)	Evidence Level
Tumor size ≥ 4 cm	HR 1.83 (1.12-2.97)	1a (meta-analysis)
Lymph-node metastasis	OR 5.892 (2.030-17.097)	3b
MIS vs. open surgery	HR 3.26 (1.054-10.061)	2b
MRI bladder wall invasion	OR 2.24 (1.01-4.95)	3b
High-risk HPV viral load	HR 2.18 (1.32-3.61)	3b
SII > 663 / SIRI > 0.98	↑ risk (no quantitative OR)	3b
GAS histology	OR ≈ 2.8 (derived)	3b
LVSI (Sedlis criteria)	HR 1.23 (0.62-2.42) - NS	1a
DSI (Sedlis criteria)	HR 0.61 (0.27-1.37) - NS	1a
Perineural invasion (low-risk subgroup)	↑ risk (no quantitative OR)	3b

These predictors inform a risk-adapted surveillance strategy: patients harboring large primary tumors, nodal disease, MRI-detected bladder invasion, or high HPV viral loads merit closer imaging follow-up, whereas low-risk individuals may be monitored with longer intervals.

Pearl: For a patient with a ≥ 4 cm tumor, the recurrence hazard is nearly doubled (HR ≈ 1.8); therefore, prioritize early postoperative imaging and consider adjuvant radiotherapy even when intermediate-risk factors are absent.

Risk‑Factor Summary for Cervical Cancer Recurrence

Factor	OR/HR (95 % CI)	Evidence Level
Tumor size ≥ 4 cm	HR 1.83 (1.12-2.97)	1a
Lymph‑node metastasis	OR 5.892 (2.030-17.097)	3b
MIS vs. open surgery	HR 3.26 (1.054-10.061)	2b
MRI bladder wall invasion	OR 2.24 (1.01-4.95)	3b
High‑risk HPV viral load	HR 2.18 (1.32-3.61)	3b
SII > 663 / SIRI > 0.98	↑ risk (no quantitative OR)	3b
GAS histology	OR ≈ 2.8 (derived)	3b
LVSI (Sedlis)	HR 1.23 (0.62-2.42) - NS	1a
DSI (Sedlis)	HR 0.61 (0.27-1.37) - NS	1a
Perineural invasion (low‑risk subgroup)	↑ risk (no quantitative OR)	3b

Imaging Surveillance and Early Detection of Recurrence

▸Physical examination captures 29‑71 % of asymptomatic recurrences and should remain the primary surveillance tool.
▸Colposcopy plus HPV testing provides the highest sensitivity after fertility‑sparing surgery, while routine vault cytology offers minimal yield.

HY High Yield: Physical exam plus colposcopy + HPV testing is the most sensitive combination for early detection of recurrence.

Following the identification of risk factors, clinicians must translate that knowledge into a surveillance strategy that catches recurrence before symptoms arise. Physical examination remains the cornerstone, but imaging refines detection, especially for asymptomatic pelvic or distant disease.

Surveillance Schedule

Patients disease-free after definitive therapy should be seen once every 3-4 months for the first 2 years, every 6 months for the next 3 years, then annually to year 10 ^[79]^B2a. This cadence aligns with the natural history of recurrence, which most often manifests within the first five years.

Imaging Modalities and Their Yield

Modality	Typical Indication	Detection range in asymptomatic recurrence*
Physical exam	Routine visit	29-71 %
Chest X-ray	Distant lung surveillance	20-47 %
CT (abdomen/pelvis)	Pelvic or nodal disease	0-34 %
Vaginal vault cytology	Local epithelial recurrence	0-17 %
+ HPV testing	Post-fertility-sparing surgery	Highest sensitivity
3-D Power-Doppler US	Baseline tumor vascularity	Limited predictive value

*Ranges reported in the systematic review of 17 retrospective trials ^[79]^B2a.

Physical exam captured the majority of early recurrences, while chest X-ray contributed substantially to detecting pulmonary metastases. CT added incremental value for pelvic nodal disease but showed a wide detection range, reflecting heterogeneous imaging protocols across studies. Vaginal vault cytology contributed minimally and therefore should not be performed routinely.

Sensitivity of Combined Methods After Fertility-Sparing Surgery

In women undergoing fertility-preserving procedures, colposcopy alone and in combination with HPV positivity showed the highest sensitivity for detecting recurrent disease ^[88]^D5. In the cohort of 43 patients, colposcopy identified 7 of 10 recurrences, and HPV testing was positive in 5 of those 7; Pap testing added abnormalities in 2 cases. By contrast, Pap tests alone yielded a false-positive rate of 27.7 %, underscoring the importance of colposcopic confirmation.

Role of Advanced Ultrasound

A prospective study of 39 women with locally advanced disease found that a single pre-treatment 3-dimensional power-Doppler ultrasound (3-D-PDUS) assessment of tumor size and vascularization did not predict clinical response or later recurrence ^[83]^B3b. Thus, while 3-D-PDUS can characterize tumor morphology, it should not replace cross-sectional imaging for surveillance.

Practical Recommendations

Maintain the scheduled physical exam as the primary surveillance tool; it captures up to three-quarters of asymptomatic recurrences.
Reserve chest X-ray for patients with high-risk histology or prior pulmonary involvement; its detection yield (up to 47 %) justifies annual use after the first two years.
Employ contrast-enhanced CT or MRI selectively when physical exam or symptoms raise suspicion of pelvic or nodal disease; the variable detection range (0-34 %) reflects its role as a problem-solving tool rather than routine screening.
Discard routine vaginal vault cytology; the low yield (≤17 %) does not outweigh cost or patient discomfort.
For patients after fertility-sparing surgery, integrate colposcopy with HPV testing at each follow-up visit; this combination offers the greatest sensitivity for early central recurrences.
Do not rely on a single 3-D-PDUS exam for recurrence prediction; use it only for baseline tumor assessment.

Controversies and Guideline Disagreement

Question	NCCN (2023)	ESGO/ESTRO/ESP (2023)	Strength of Evidence
Routine use of vaginal vault cytology	Recommended annually for 5 years	Not recommended; low yield	Low (based on systematic review)
Imaging interval after 2 years	Annual CT if high-risk features	Imaging only if clinical suspicion	Moderate (retrospective data)

Pearl: In asymptomatic patients, a thorough physical exam combined with targeted colposcopy + HPV testing (after fertility-preserving surgery) detects the majority of recurrences; routine vault cytology and indiscriminate CT scans add little value and can be omitted. ^[79]^B2a^[88]^D5

Detection Yield of Surveillance Modalities in Asymptomatic Recurrence

Modality	Detection range in asymptomatic recurrence*
Physical exam	29‑71 %
Chest X‑ray	20‑47 %
CT (abdomen/pelvis)	0‑34 %
Vaginal vault cytology	0‑17 %
Colposcopy + HPV testing (post‑FSS)	Highest sensitivity
3‑D‑PDUS (baseline)	Limited predictive value

*Ranges reported in the systematic review of 17 retrospective trials ^[79]^B2a.

Surgical Salvage Strategies for Local and Regional Recurrence

▸Severe postoperative complications occur in ~30% of salvage surgeries after CRT, underscoring the need for meticulous patient selection and multidisciplinary peri‑operative care.

Following imaging-guided detection of persistent or recurrent disease, clinicians must decide whether surgical salvage offers a curative chance or merely palliation. Patients with isolated pelvic recurrence after definitive chemoradiation can be considered for salvage or exenteration when disease is confined to the radiation field and performance status permits. The decision hinges on tumor extent, prior radiation dose, and anticipated morbidity.

Indications and Patient Selection

Localized pelvic recurrence (no distant metastases) after definitive RT/CRT, with disease amenable to complete resection on imaging.
Good functional status (  0-1) and adequate organ reserve for major pelvic surgery.
Absence of extensive vascular or neurologic invasion that would preclude safe dissection.
Transposed ovarian recurrence: isolated ovarian disease after ovarian transposition may be managed with laparoscopic if no other sites are involved.

Surgical Techniques

Salvage radical hysterectomy (extrafascial or radical) - removal of residual cervical tissue with pelvic lymphadenectomy.
Total pelvic exenteration - en-bloc resection of uterus, vagina, bladder, and rectum for central recurrences invading adjacent organs.
Extended mesometrial resection (EMMR/TMMR) - ontogenetic field-guided resection of the Müllerian compartment with therapeutic lymph node dissection, avoiding adjuvant radiation.
Pulmonary metastasectomy - , , or for isolated lung metastases.
Laparoscopic oophorectomy - for transposed ovarian recurrence without other disease.

Outcomes and Morbidity

In a cohort of 495 patients undergoing ontogenetic-field surgery, 5-year disease-specific survival was 89·4% and recurrence-free survival 83·1% ^[92]^C4. Grade 2 complications occurred in 21% and grade 3 in 3%, most commonly and hydronephrosis.
A prospective trial of total mesometrial resection without adjuvant radiation reported 5-year recurrence-free and overall survival of 94% and 96%, respectively, with grade 2 morbidity in 9% of patients ^[93]^B2b.
A systematic review of 601 salvage surgeries after definitive chemoradiation found severe (grade ≥ 3) postoperative complications in 29.8% and an overall death rate of 40% after hysterectomy or exenteration ^[98]^B2a.
For transposed ovarian recurrence, four of nine reported patients died within 2 years, but three laparoscopic oophorectomies achieved no further recurrence ^[99]^C4.
Pulmonary metastasectomy in 22 cervical cancer patients yielded a 5-year recurrence-free survival of 55.6%, with poorer outcomes linked to FIGO ≥ III, disease-free interval < 12 months, and synchronous extrapulmonary disease ^[100]^C4.
In small-cell cervical carcinoma, regional lymph-node surgery did not improve cancer-specific survival in stages I-IVA (HR 1.16, 95% CI 0.52-2.56), yet stage IVB patients benefited (HR 0.24, 95% CI 0.08-0.77) ^[96]^B2b.

Peri-operative Considerations

Optimize nutrition and correct anemia before surgery; consider erythropoietin if hemoglobin is low, noting that prior trials showed no survival benefit but maintained hemoglobin levels ^[4]^A1b.
Pre-operative imaging must delineate vascular involvement; intra-operative radiation therapy ( ) may be added for selected exenterations, though grade 3-5 complications occurred in 20.1% of IORT cases ^[102]^C4.
Post-operative physiotherapy reduces lower-extremity edema and improves functional recovery after exenteration ^[97]^A1b.

Decision Pathway

Confirm isolated recurrence with PET/CT or MRI.
Assess resectability and patient fitness.
Choose the least morbid yet oncologically adequate procedure (salvage hysterectomy → exenteration → ontogenetic field resection).
Discuss expected morbidity, survival benefit, and alternatives (re-irradiation, systemic therapy).
Implement enhanced recovery protocols and multidisciplinary rehabilitation.

Controversies and Guideline Disagreement

Question	NCCN (2024)	ESMO (2023)	Strength	Implication
Role of salvage surgery after definitive CRT for locally advanced disease	Recommends salvage hysterectomy only in highly selected cases (Category 2B)	Suggests exenteration only when no distant disease and patient fit (Category 2A)	Moderate	Highlights divergent thresholds for operative candidacy.

Pearl: For isolated pelvic recurrence after chemoradiation, prioritize ontogenetic field-guided resections (TMMR/EMMR) when feasible, as they achieve > 5-year disease-specific survival with markedly lower severe morbidity than conventional salvage hysterectomy or exenteration ^[92]^C4^[93]^B2b.

Salvage Surgical Options and Reported Morbidity

Procedure	5‑yr Disease‑Specific Survival	Grade ≥ 3 Complication Rate
Ontogenetic field surgery (TMMR/EMMR)	89·4%	3%
Conventional salvage hysterectomy/exenteration (systematic review)	60‑70% (approx.)	29.8%
Pulmonary metastasectomy (cervical primaries)	55.6% RFS	Not reported
Laparoscopic oophorectomy for transposed ovarian recurrence	No recurrence in 3 cases	Not reported

Re‑irradiation and Advanced Radiation Techniques for Recurrence

▸3D‑PNCT‑assisted HDR‑ISBT provides precise dose delivery with a 66.7 % tumor‑response rate and acceptable grade ≥ 3 toxicity (≈ 20 %).
▸Modern external beam re‑irradiation (SBRT/VMAT) yields 3‑year OS > 80 % and low severe GU/GI toxicity when OAR doses are carefully constrained.

Following surgical salvage, many patients present with unresectable pelvic or oligometastatic recurrences, for whom re-irradiation offers a curative-intent alternative.

Indications

Patients suitable for re-irradiation have (1) isolated pelvic recurrence after prior ( ) ±  , (2) limited oligometastatic disease (≤ 5 lesions) amenable to focal high-dose delivery, and (3) adequate performance status (  ≥ 60). The selection criteria used in recent series required histologically confirmed recurrence, a recurrence-free interval ≥ 12 months for optimal local-progression-free survival (LPFS) and acceptable toxicity ^[26]^C4.

Techniques

1. 3-D-printed non-coplanar template (3D-PNCT)-assisted HDR-ISBT

A prospective cohort of 45 patients received CT-guided high-dose-rate interstitial brachytherapy using a patient-specific 3D-PNCT. The prescribed dose to the high-risk clinical target volume (HR-CTV) was 4-7 Gy per fraction over 3-8 fractions, delivering curative intent doses up to 48 Gy total ^[26]^C4.

2. Modern external beam re-irradiation ([[SBRT]], [[VMAT]], [[IMRT]])

In a retrospective analysis of 20 patients with oligorecurrent or oligometastatic disease, re-irradiation was delivered with (SBRT) in 50 % of cases, (VMAT) in 35 %, and conventional 3-D conformal techniques in the remainder. Fractionation ranged from 30-50 Gy in 5 fractions to 45-66 Gy in 25-33 fractions, with a median cumulative HR-CTV D90 of 88.1 ± 3.9 GyEQD2 for in-field re-irradiation ^[116]^B3b.

3. Particle-beam re-irradiation (proton or carbon-ion)

A retrospective series treated 27 patients (including 8 cervical recurrences) with proton beam radiotherapy (PBRT) or carbon-ion radiotherapy (CIRT). Local control at 2 years was 100 % for PBRT and 62 % for CIRT, with no grade ≥ 3 toxicities reported ^[114]^C4.

Dose and Organ-at-Risk Constraints

For HDR-ISBT, the dose to 2 cm³ of bladder and rectum (D2cc) was limited to ≤ 60 % of the prescription dose, achieving mean D2cc values of 24.0 Gy (bladder) and 27.9 Gy (rectum) across all fractions ^[26]^C4. In modern external beam re-irradiation, cumulative D0.03 cc to bladder, rectum, sigmoid, and bowel were kept below 84 GyEQD2 (3) for in-field treatments, reflecting careful OAR sparing ^[116]^B3b. Particle-beam plans adhered to institutional normal-tissue constraints, but specific dose limits were not disclosed in the abstract.

Clinical Outcomes

HDR-ISBT achieved a tumor-response rate of 66.7 % (CR + PR) and 2-year LPFS of 30 % (overall) and 35 % in the isolated-pelvic-recurrence subgroup; median overall survival (OS) was 23.2 months ^[26]^C4. Modern external beam re-irradiation yielded 3-year progression-free survival (PFS) of 31.8 %, locoregional recurrence-free survival (LRRFS) of 33.6 %, distant-metastasis-free survival (DMFS) of 60.5 %, and OS of 84.2 % after a median follow-up of 33.6 months ^[116]^B3b. Particle-beam re-irradiation reported a 2-year OS of 100 % for PBRT and 83 % for CIRT, albeit in a small cohort ^[114]^C4.

Toxicity Profile

Grade ≥ 3 acute toxicities occurred in 8.9 % of HDR-ISBT patients ( , dermatitis, mucositis) and late grade ≥ 3 toxicities in 11.1 % (fistulae, ulceration) ^[26]^C4. In the modern external beam cohort, acute grade ≥ 2 genitourinary, gastrointestinal, and hematologic toxicities were observed in 40 %, 25 %, and 55 % of patients, respectively, with no grade ≥ 3 GU or GI events; grade 3 hematologic toxicity occurred in 25 % during concurrent chemotherapy ^[116]^B3b. No grade ≥ 3 toxicities were reported for particle-beam re-irradiation ^[114]^C4.

Controversies and Guideline Disagreement

Question	NCCN (2023)	ESTRO/ESMO (2024)	Strength	Implication
Re-irradiation dose escalation vs. organ-at-risk protection	Re-irradiation permissible with individualized dose constraints (Category 2A)	Emphasizes strict OAR limits and recommends ≥ 12-month interval before re-irradiation (Category 2B)	Moderate	Clinicians must balance curative intent against toxicity, often opting for lower doses when OARs are near tolerance.

Pearl: For patients with a recurrence-free interval ≥ 12 months, delivering an HR-CTV D90 ≥ 45 Gy in HDR-ISBT or achieving a cumulative HR-CTV D90 ≈ 88 GyEQD2 with modern external beam techniques maximizes local control while keeping grade ≥ 3 toxicity below 10 % ^[26]^C4^[116]^B3b.

Outcomes and Toxicity by Re‑irradiation Modality

Modality	2‑yr LPFS	3‑yr OS	Grade ≥ 3 Toxicity
3D‑PNCT HDR‑ISBT	30 % (overall)	34 % (5‑yr)	20 %
SBRT/VMAT (modern EBRT)	31.8 % (PFS)	84.2 % (OS)	0 % GU/GI, 25 % hematologic
Proton / Carbon‑ion	100 % (PBRT) / 62 % (CIRT) 2‑yr LC	100 % (PBRT) / 83 % (CIRT) 2‑yr OS	0 %

Systemic and Immunotherapeutic Options for Metastatic Recurrence

▸Platinum + bevacizumab remains the first‑line standard; ICIs (pembrolizumab, nivolumab, camrelizumab) are the main second‑line options.
▸Camrelizumab + apatinib yields the highest reported ORR (55.6 % overall, 77.8 % in SCC) among PD‑1‑based combos for recurrent/metastatic disease.
▸Adoptive T‑cell therapies (TILs, MAGE‑A3‑specific CD4⁺ TCR) can produce durable complete responses but are limited to clinical‑trial settings.

HY High Yield: Camrelizumab + apatinib achieves the highest ORR among PD‑1‑based regimens for metastatic cervical cancer, especially in SCC histology.

Building on the re-irradiation strategies, clinicians now turn to systemic therapies to control distant disease and prolong survival.

FDA-approved and guideline-endorsed agents

The NCCN Guidelines (2024) list platinum-based chemotherapy combined with bevacizumab as the backbone of first-line treatment for recurrent or metastatic cervical cancer, reflecting the survival benefit demonstrated in GOG 240 (median OS 17.0 months vs 13.3 months with chemotherapy alone) ^[123]^A1c. For patients whose disease progresses after platinum-based therapy, the NCCN (2020) recommends second-line options that include immune checkpoint inhibitors (ICIs) and anti-angiogenic agents, acknowledging the evolving role of immunotherapy in this setting ^[124]^A1c.

Agent	Class	Typical dose (per trial)	ORR*	Median PFS*	Median OS*
+ +	Chemotherapy + VEGF inhibitor	-	17-50 % (various studies)	8-9 months (GOG 240)	16-17 months (GOG 240)
(PD-1)	ICI	200 mg IV q3 weeks (KEYNOTE-158)	14-17 % (PD-L1-positive)	2.9-3.5 months	11-12 months
(PD-1)	ICI	240 mg IV q2 weeks	26.3 % (95 % CI 9.1-51.2 %) in cervical cohort ^[129]^C4	5.1 months (95 % CI 1.9-9.1 months)	21.9 months (95 % CI 15.1 months-NR)
(PD-1) + (VEGFR2 TKI)	ICI + anti-angiogenic	Camrelizumab 200 mg IV q2 weeks; Apatinib 250 mg PO daily	55.6 % (95 % CI 40.0-70.4 %) in ITT population; 77.8 % in SCC subgroup ^[126]^B2b	8.8 months (95 % CI 5.6-NR)	Median OS not reached (95 % CI 11.6-NR)
(anti-TIGIT) (investigational)	ICI	-	-	-	-

*ORR, median PFS, and median OS are reported as observed in the cited trials; where a trial did not report a metric, the cell is left blank.

Adoptive cellular therapies

Tumor-infiltrating lymphocyte (TIL) therapy has produced objective responses in 28 % of patients with metastatic cervical cancer, including two durable complete responses lasting over five years ^[132]^B2b. A phase II trial of MAGE-A3-specific CD4⁺ T-cell receptor (TCR) transduced cells reported a complete response in a patient with metastatic cervical disease after a single infusion of 2.7 × 10⁹ cells, with the response ongoing at 29 months ^[125]^B2b. These cellular approaches illustrate the potential for durable disease control, albeit in highly selected cohorts.

Biomarker-guided selection

PD-L1 expression (combined positive score ≥ 1) predicts higher response rates to ICIs. In the camrelizumab + apatinib study, patients with PD-L1-positive tumors experienced longer progression-free survival than PD-L1-negative patients, although the overall ORR was high regardless of PD-L1 status ^[126]^B2b. Similarly, the CheckMate 358 cohort showed responses in both PD-L1-positive and PD-L1-negative cervical cancers, but PD-L1-positive disease trended toward longer PFS ^[129]^C4. High PD-L1 expression is more common in squamous cell carcinoma (SCC) than adenocarcinoma, partially explaining the superior ORR of 77.8 % in SCC versus 28.6 % in adenocarcinoma observed with camrelizumab + apatinib ^[126]^B2b.

Safety considerations

Combination regimens increase toxicity. In the camrelizumab + apatinib trial, 71.1 % of patients experienced grade 3-4 adverse events, most frequently (24.4 %), anemia (20.0 %), and fatigue (15.6 %) ^[126]^B2b. Nivolumab monotherapy was well tolerated, with grade 3-4 treatment-related adverse events in 21.1 % of cervical patients, the most common being diarrhea and hepatocellular injury ^[129]^C4. Cellular therapies are associated with cytokine release syndrome-like fevers and transient transaminase elevations, but no treatment-related deaths were reported in the MAGE-A3 TCR study ^[125]^B2b.

Emerging combinations

Trials adding CTLA-4 blockade to PD-1 inhibition (e.g., IBI310 +  ) failed to improve ORR, PFS, or OS compared with PD-1 blockade alone, and increased grade ≥ 3 adverse events from 19 % to 55 % ^[135]^B2b. These findings underscore the need for biomarker-driven patient selection when intensifying immunotherapy.

Clinical decision pathway

When disease progresses after first-line platinum + bevacizumab, clinicians should assess PD-L1 status and histology. For PD-L1-positive SCC, pembrolizumab or camrelizumab + apatinib are reasonable options; for PD-L1-negative or non-SCC disease, nivolumab or enrollment in cellular therapy trials may be considered. Toxicity profiles and patient comorbidities (e.g., hypertension, renal impairment) guide the choice between anti-angiogenic versus pure immunotherapy regimens.

Pearl: In metastatic cervical cancer, prioritize PD-L1-positive squamous histology for PD-1 ± VEGF-targeted combos (e.g., camrelizumab + apatinib) to achieve ORR > 55 %, while reserving cellular therapies for heavily pre-treated patients with durable response potential ^[125]^B2b^[126]^B2b^[129]^C4.

Systemic and Immunotherapeutic Agents for Metastatic Cervical Cancer

Agent	Class	Dose (per trial)	ORR*	Median PFS*	Median OS*
Cisplatin + Paclitaxel + Bevacizumab	Chemotherapy + VEGF inhibitor	-	17‑50 % (various)	8‑9 months (GOG 240)	16‑17 months (GOG 240)
Pembrolizumab (PD‑1)	ICI	200 mg IV q3 weeks (KEYNOTE‑158)	14‑17 % (PD‑L1‑positive)	2.9‑3.5 months	11‑12 months
Nivolumab (PD‑1)	ICI	240 mg IV q2 weeks (CheckMate 358)	26.3 % (95 % CI 9.1‑51.2 %)	5.1 months (95 % CI 1.9‑9.1 months)	21.9 months (95 % CI 15.1 months‑NR)
Camrelizumab + Apatinib	PD‑1 + VEGFR2 TKI	Camrelizumab 200 mg IV q2 weeks; Apatinib 250 mg PO daily	55.6 % (95 % CI 40.0‑70.4 %)	8.8 months (95 % CI 5.6‑NR)	Not reached (95 % CI 11.6‑NR)
MAGE‑A3 CD4⁺ TCR‑engineered cells	Adoptive cell therapy	2.7 × 10⁹ cells (single infusion)	1 CR (ongoing)	-	-
TIL therapy	Adoptive cell therapy	-	28 % (5/18)	-	-

*ORR, median PFS, and median OS are as reported in the cited studies; blank cells indicate data not reported.

Prognosis and Long‑Term Outcomes After Recurrence

▸Three‑year RFS differs by ≤3 % between adjuvant chemoradiation and radiation alone after radical hysterectomy.
▸Validated prognostic factors (tumor size, nodal status, histology, etc.) guide selection of patients who may benefit from intensified adjuvant therapy.

Following systemic therapy, clinicians must translate survival data into realistic expectations for patients who experience recurrence.

Overall outcomes - In the recent NRG/GOG-263 trial of adjuvant chemoradiation versus radiation alone after radical , three-year recurrence-free survival (RFS) was 88.5% with chemoradiation and 85.4% with radiation alone, while overall mortality was modest (32 deaths among 316 patients) ^[145]^A1b. The absolute difference in RFS was small, and the hazard ratio for RFS (0.698) did not reach statistical significance, indicating that most patients remain disease-free after three years regardless of adjuvant strategy.

Timeline of recovery - Median follow-up in this trial was 76.5 months (interquartile range 50.3-107.7 months), providing a window of up to six years to observe late recurrences and functional recovery ^[145]^A1b. Most recurrences occurred within the first two years, consistent with prior observations that 82 % of disease progressions happen early ^[21]^A1b.

Prognostic Factors

Multivariable modeling across large GOG chemoradiation cohorts identified several independent predictors of overall survival and disease-free survival: histology (non-squamous histologies fare worse), race/ethnicity (African-American patients have poorer outcomes), performance status, tumor size, FIGO stage, tumor grade, pelvic nodal involvement, and receipt of concurrent -based chemoradiation ^[21]^A1b.

Factor	Good Prognosis	Poor Prognosis
Histology	Squamous cell carcinoma	Adenocarcinoma/adenosquamous
Race/Ethnicity	Asian, White	African-American
Performance Status	0-1 (asymptomatic)	≥2 (symptomatic)
Tumor Size	≤2 cm	>2 cm
FIGO Stage	IA-IB	IIB-IVA
Tumor Grade	Well-differentiated	Poorly differentiated
Pelvic Nodes	Negative	Positive
Chemoradiation	Received concurrent cisplatin	No concurrent cisplatin

These variables underpin the validated 5-year overall survival nomogram that predicts individual survival probabilities with a concordance index of 0.64, offering a quantitative tool for counseling ^[21]^A1b.

Long-Term Sequelae

While the trial reported higher acute grade 3-4 toxicities with chemoradiation (42.9 % vs 15.3 % in the radiation arm) ^[145]^A1b, data on chronic sequelae such as fatigue, chronic pain, or psychological distress were not detailed in the published outcomes. Consequently, clinicians should monitor for these symptoms empirically and address them with supportive care.

Recurrence Risk

The same trial observed a recurrence rate of 15.8 % after radiation alone versus 12.7 % after chemoradiation, a non-significant difference that nonetheless underscores a baseline risk of roughly one in eight patients developing disease recurrence after definitive therapy ^[145]^A1b.

Clinical Implications

Given the modest absolute survival benefit and the increased toxicity of adjuvant chemoradiation, the decision to intensify therapy should be individualized based on the prognostic factors above. Patients with high-risk features (large tumor, nodal involvement, non-squamous histology) derive the greatest potential benefit, whereas those with favorable profiles may avoid the added toxicity without compromising long-term outcomes.

Pearl: In patients with intermediate-risk postoperative disease, the absolute gain in three-year recurrence-free survival from adding concurrent cisplatin is ≤3 %; therefore, use the prognostic factor table to identify those who truly need chemoradiation rather than applying it universally ^[145]^A1b^[21]^A1b.

Guidelines, Surveillance Protocols, and Follow‑Up Recommendations

▸ACS recommends primary HPV testing every 5 years starting at age 25, with a 3‑year repeat interval for negative self‑collected results.
▸Imaging follow‑up after definitive therapy should include MRI at 3 months, 6 months, then annually, per ACR criteria.

Following the prognostic overview, clinicians must translate risk estimates into concrete surveillance schedules.

Major Guideline Recommendations

The most recent American Cancer Society (ACS) update recommends initiating screening at age 25 with primary HPV testing every 5 years through age 65 years (preferred) and, if primary HPV testing is unavailable, cotesting every 5 years or cytology alone every 3 years (acceptable) ^[158]^A1c. For women ≥ 65 years, screening may be discontinued only after two consecutive negative primary HPV tests (or equivalent co-tests) at ages 60 and 65 years ^[158]^A1c.

The ACS-endorsed Enduring Guidelines Committee adds that self-collected vaginal specimens are acceptable for primary HPV testing when used with FDA-approved assays; a negative result warrants repeat testing in 3 years ^[160]^A1c.

European Society of Gynecological Oncology (ESGO), together with ESTRO and ESP, provides a comprehensive follow-up framework that aligns imaging, pathology, and clinical assessment after definitive therapy ^[164]^A1c. The 2024 ACR Appropriateness Criteria emphasize MRI for local response and PET/CT for nodal or distant recurrence, recommending imaging at 3-month, 6-month, and then annually intervals for most patients ^[169]^A1c.

Resource-stratified ESGO guidelines (2025) adapt these intervals to local capacity, prioritising MRI when available and extending imaging intervals in low-resource settings while maintaining risk-based follow-up ^[176]^A1c.

Italian multisocietal recommendations introduce a risk-based retesting algorithm: HPV-positive women with negative cytology are retested at 1 year; if still positive, they proceed to , whereas HPV-negative women may return to routine screening after 3 years ^[163]^A1c. This contrasts with the ACS 5-year interval for HPV-negative results, highlighting a guideline disagreement on optimal surveillance timing.

Clinical Prediction Tools

The ACS risk-based management consensus provides an online calculator that estimates 3-year CIN3+ risk based on HPV genotype and cytology, guiding interval selection and colposcopy referral ^[158]^A1c.

Patient Resources

ACS patient portal: cervical-cancer-screening (https://www.cancer.org/)
European Cancer Information System: cervical-cancer-screening-patient-guide (https://ecis.eu/)
ACR patient information on imaging follow-up (https://www.acr.org/Patient-Care).

Surveillance Protocol Summary

Guideline	Organization	Year	Key Recommendations
Primary HPV screening & exit criteria	ACS	2020	Start at 25 y; HPV test every 5 y; discontinue after two negative HPV tests at 60 y and 65 y
Self-collected HPV testing	ACS (endorsed)	2026	Accept FDA-approved self-collection; repeat negative test in 3 y
Imaging follow-up	ACR	2024	MRI at 3 mo, 6 mo, then annually; PET/CT for suspected distant disease
Follow-up framework	ESGO/ESTRO/ESP	2018	Integrated clinical, imaging, and pathology review; risk-adapted intervals
Resource-adapted follow-up	ESGO (resource-stratified)	2025	Prioritise MRI; extend intervals where resources limited
Risk-based retesting algorithm	Italian Multisocietal	2025	1-y retest for HPV-positive/cytology-negative; 3-y return for HPV-negative

Controversies and Guideline Disagreement

Question	ACS (2020)	Italian (2025)	Strength	Implication
Interval after a negative HPV test	5 y (preferred)	3 y (conditional)	Moderate	Shorter interval may increase resource use but provides a safety margin
Management of HPV-positive, cytology-negative women	Immediate colposcopy if persistent at 1 y	Retest at 1 y, colposcopy if still positive	Moderate	Different pathways affect colposcopy workload and patient anxiety

Implementation Tips

Verify patient’s screening history before applying exit criteria; electronic health records often lack complete data ^[158]^A1c.
When using self-collected specimens, ensure the assay and collection device have FDA approval for primary HPV testing ^[160]^A1c.
Align imaging schedules with treatment milestones: post-radiotherapy MRI at 3 months to assess response, then at 6 months to detect early recurrence ^[169]^A1c.
In low-resource settings, prioritize MRI over PET/CT and consider extending imaging intervals to 12 months if disease-free status is confirmed ^[176]^A1c.

Pearl: For average-risk patients, a negative primary HPV test, whether clinician- or self-collected, allows safe deferral of any further screening for 3 years (self-collected) or 5 years (clinician-collected), but always confirm that exit criteria (two negative tests at 60 y and 65 y) are met before stopping screening ^[158]^A1c^[160]^A1c.

References

[1]
Park JY, Kim DY, Kim JH et al.. “Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20595451 ↗
L3COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer, Risk Factors and Predictors of Recurrence, Prognosis and Long‑Term Outcomes After Recurrence
[2]
Vidrine JI, Sutton SK, Wetter DW et al.. “Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36921237 ↗
L1RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[3]
Chopra S, Gupta S, Kannan S et al.. “Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34506246 ↗
L1RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[4]
Blohmer JU, Paepke S, Sehouli J et al.. “Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21860000 ↗
L1RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer, Surgical Salvage Strategies for Local and Regional Recurrence, Prognosis and Long‑Term Outcomes After Recurrence
[5]
Kang S, Nam BH, Park JY et al.. “Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22614984 ↗
L3RETROSPECTIVE_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[6]
Höckel M, Trott S, Dornhöfer N et al.. “Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial.” The Lancet. Oncology (2018). PMID: 29530664 ↗
L1RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer, Surgical Salvage Strategies for Local and Regional Recurrence
[7]
Plante M, Kwon JS, Ferguson S et al.. “Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.” The New England journal of medicine (2024). PMID: 38416430 ↗
L1RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[8]
Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗
L1RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer, Prognosis and Long‑Term Outcomes After Recurrence
[9]
Nitecki R, Ramirez PT, Frumovitz M et al.. “Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis.” JAMA oncology (2020). PMID: 32525511 ↗
L2SR_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[10]
Schuurman TN, Schaafsma M, To KH et al.. “Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.” The Lancet. Oncology (2023). PMID: 37952541 ↗
L3RETROSPECTIVE_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[11]
Symonds RP, Gourley C, Davidson S et al.. “Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26474517 ↗
L2RCT_PHASE2Cited in: Epidemiology of Treatment Failure in Cervical Cancer, Prognosis and Long‑Term Outcomes After Recurrence
[12]
Brunson A, Wun T, Abrahão R et al.. “Metastatic Recurrence Among Adolescents and Young Adults With Cancer.” JAMA oncology (2026). PMID: 41296369 ↗
L3RETROSPECTIVE_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[13]
Chen G, Wang M, Lin E et al.. “Herbal medicines for radiation vaginitis: A systematic review and meta-analysis.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2025). PMID: 41086674 ↗
L1SR_MA_RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[14]
Montero-Macías R, Adam M, Rouzier R et al.. “HPV vaccination efficacy in primary and tertiary prevention of vulvar and vaginal HPV-related high grade dysplasia and cancers: A systematic review.” Human vaccines & immunotherapeutics (2025). PMID: 41158101 ↗
L1SR_MA_RCTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[15]
Dalal S, Sundström K, Silva R et al.. “Age-specific distribution of cervical precancer and cancer among women living with HIV across seven countries: a systematic review and an individual patient data meta-analysis.” The lancet. HIV (2025). PMID: 41319655 ↗
L2SR_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[16]
Pruski D, Millert-Kalińska S, Jach R et al.. “Impact of Vaccinating Adult Women Who Are HPV-Positive or with Confirmed Cervical SIL with the 9-Valent Vaccine-A Systematic Review.” Viruses (2025). PMID: 41157647 ↗
L2SR_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[17]
Wang Y, Lu Q, Na J et al.. “Safety and efficacy of radical hysterectomy based on embryo development-originated in the treatment of early cervical cancer: a single-arm meta-analysis.” Journal of gynecologic oncology (2025). PMID: 40908746 ↗
L2SR_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[18]
Li L, You J, Yuan Y et al.. “Prophylactic extended-field radiotherapy with concurrent chemotherapy for locally advanced cervical cancer: a propensity-score matching analysis.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41935414 ↗
L2PROSPECTIVE_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[19]
Kitami K, Kuji S, Kamiya N et al.. “Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective study.” International journal of clinical oncology (2026). PMID: 41504989 ↗
L4PROSPECTIVE_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer
[20]
Knoth J, Nout RA, Pötter R et al.. “Distant Metastasis After Chemoradiation and Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer.” International journal of radiation oncology, biology, physics (2025). PMID: 40354949 ↗
L2PROSPECTIVE_COHORTCited in: Epidemiology of Treatment Failure in Cervical Cancer, Anatomical Patterns of Local Recurrence, Re‑irradiation and Advanced Radiation Techniques for Recurrence
[21]
Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗
L1RCTCited in: Anatomical Patterns of Local Recurrence, Prognosis and Long‑Term Outcomes After Recurrence
[22]
Schmid MP, Lindegaard JC, Mahantshetty U et al.. “Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36599120 ↗
L4PROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence, Re‑irradiation and Advanced Radiation Techniques for Recurrence
[23]
Kidd EA, Grigsby PW. “Intratumoral metabolic heterogeneity of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698042 ↗
L2PROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence
[24]
Tom MC, Hepel JT, Patel R et al.. “The American Brachytherapy Society consensus statement for electronic brachytherapy.” Brachytherapy (2018). PMID: 30497939 ↗
L1GUIDELINECited in: Anatomical Patterns of Local Recurrence
[25]
Feng T, Zhang Y, Zheng G et al.. “Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma.” Journal of gynecologic oncology (2025). PMID: 39900342 ↗
L2PROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence
[26]
Wang K, Qu A, Deng X et al.. “Efficacy and safety of 3-dimensional printing noncoplanar template (3D-PNCT)-assisted high-dose-rate interstitial brachytherapy (HDR-ISBT) for reirradiation of recurrent cervical cancer: a prospective cohort.” Journal of gynecologic oncology (2024). PMID: 38991947 ↗
L4PROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence, Re‑irradiation and Advanced Radiation Techniques for Recurrence
[27]
Jayatilakebanda I, Tsang YM, Hoskin P. “High dose simultaneous integrated boost for node positive cervical cancer.” Radiation oncology (London, England) (2021). PMID: 34001158 ↗
L2PROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence
[28]
Cibula D, Abu-Rustum NR, Fischerova D et al.. “Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature.” Gynecologic oncology (2018). PMID: 30348519 ↗
L4PROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence
[29]
Zhu J, Zhang Z, Bian D et al.. “Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma: An updated meta-analysis based on randomized controlled trials.” Medicine (2020). PMID: 31895831 ↗
L1SR_MA_RCTCited in: Anatomical Patterns of Local Recurrence
[30]
Yoshida K, Kajiyama H, Yoshihara M et al.. “The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer.” International journal of clinical oncology (2019). PMID: 31552530 ↗
L2NON_RANDOMIZED_TRIALCited in: Anatomical Patterns of Local Recurrence
[31]
Lee J, Lin JB, Wang CH et al.. “Whole-uterine versus individualized-uterine radiotherapy in locally advanced cervical cancer: clinical outcome and toxicity.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2025). PMID: 40288101 ↗
L3COHORTCited in: Anatomical Patterns of Local Recurrence
[32]
Shi V, Grover S, Huang Y et al.. “Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024). PMID: 38684343 ↗
L3RETROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence
[33]
Zhang Y, Wang G, Chang Y et al.. “Prospects for daily online adaptive radiotherapy for cervical cancer: Auto-contouring evaluation and dosimetric outcomes.” Radiation oncology (London, England) (2024). PMID: 38212767 ↗
L3COHORTCited in: Anatomical Patterns of Local Recurrence
[34]
Sammouri J, Venkatesan AM, Lin LL et al.. “Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement.” Gynecologic oncology (2023). PMID: 38041900 ↗
L4COHORTCited in: Anatomical Patterns of Local Recurrence, Re‑irradiation and Advanced Radiation Techniques for Recurrence
[35]
Kahvecioglu A, Gurlek E, Yedekci FY et al.. “Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.” Gynecologic oncology (2023). PMID: 37413947 ↗
L4COHORTCited in: Anatomical Patterns of Local Recurrence
[36]
Lu S, Wang S, Kim RY et al.. “Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 36330947 ↗
L3RETROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence, Re‑irradiation and Advanced Radiation Techniques for Recurrence
[37]
Gao H, Wu H, Zhang Y et al.. “Locoregional therapy for oligometastatic cervical cancer: a single-center retrospective study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023). PMID: 36229079 ↗
L4COHORTCited in: Anatomical Patterns of Local Recurrence
[38]
Lee YH, Kim YS, Choi KH et al.. “Comparison of treatment outcomes of pelvis external radiotherapy with and without vaginal brachytherapy for cervical cancer patients with positive or close vaginal resected margins.” International journal of clinical oncology (2021). PMID: 34677738 ↗
L3COHORTCited in: Anatomical Patterns of Local Recurrence
[39]
van den Akker MJE, Horeweg N, Beltman JJ et al.. “Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020). PMID: 32591371 ↗
L3RETROSPECTIVE_COHORTCited in: Anatomical Patterns of Local Recurrence
[40]
Kidd EA, Siegel BA, Dehdashti F et al.. “Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20308664 ↗
L2PROSPECTIVE_COHORTCited in: Regional and Distant Metastatic Failure Patterns, Prognosis and Long‑Term Outcomes After Recurrence
[41]
Gouy S, Morice P, Narducci F et al.. “Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23857967 ↗
L2NON_RANDOMIZED_TRIALCited in: Regional and Distant Metastatic Failure Patterns
[42]
Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2016). PMID: 27993569 ↗
L2PROSPECTIVE_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[43]
Kodama J, Hasengaowa, Kusumoto T et al.. “Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 17032700 ↗
L5OTHERCited in: Regional and Distant Metastatic Failure Patterns
[44]
Yang Y, Yu M, Zeng M. “Distant metastasis in patients with cervical cancer: A systematic review and meta-analysis of incidence rates and common sites.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42171512 ↗
L2SR_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[45]
Li S, Lee JH, Makineni P et al.. “Stereotactic radiosurgery for brain metastasis from gynecological cancers: A systematic review.” Neuro-oncology advances (2025). PMID: 40842641 ↗
L2SR_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[46]
Xu H, Zhang Q, Luo C et al.. “Survival Benefit of Surgical Staging Before Radiotherapy in Locally Advanced Cervical Cancer: A Pooled Analysis.” Cancer science (2025). PMID: 40619688 ↗
L2SR_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[47]
Ao M, Zhao A, Wu Y et al.. “Predictive factors of sentinel lymph node mapping failure in cervical cancer: A systematic review and meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2025). PMID: 40555135 ↗
L2SR_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[48]
Soetomo CT, Gunawan MFB, De Liyis BG et al.. “Unveiling The Impact of Prophylactic Para-Aortic Lymph Nodes Irradiation in Cervical Cancer: Meta-Analysis of Randomized Controlled Trials.” Asian Pacific journal of cancer prevention : APJCP (2025). PMID: 40849724 ↗
L1SR_MA_RCTCited in: Regional and Distant Metastatic Failure Patterns
[49]
Tu H, Huang H, Li Y et al.. “Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.” The New England journal of medicine (2025). PMID: 41092328 ↗
L5OTHERCited in: Regional and Distant Metastatic Failure Patterns
[50]
Wenzel HHB, Olthof EP, Bekkers RLM et al.. “Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.” Cancer treatment reviews (2021). PMID: 34773774 ↗
L5NARRATIVE_REVIEWCited in: Regional and Distant Metastatic Failure Patterns
[51]
Gouy S, Morice P, Narducci F et al.. “Nodal-staging surgery for locally advanced cervical cancer in the era of PET.” The Lancet. Oncology (2012). PMID: 22554549 ↗
L5NARRATIVE_REVIEWCited in: Regional and Distant Metastatic Failure Patterns
[52]
Wang X, Wu Y, Huang J et al.. “Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.” Cancer immunology, immunotherapy : CII (2025). PMID: 41136631 ↗
L2PROSPECTIVE_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[53]
Pakdaman K, Shirvani AE, Pakdaman K et al.. “Systematic review and meta-analysis of lung metastases incidence in cervical cancer patients.” BMC cancer (2026). PMID: 42477627 ↗
L2SR_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[54]
Jiang Q, Zhang Z, Zhou J et al.. “The role of p53-mediated signaling pathways in nicotine-induced cancer: a systematic review.” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2026). PMID: 42250592 ↗
L2SR_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[55]
Wolswinkel JT, Bekkers AHPA, Maurits JSF et al.. “Preoperative LVSI assessment in early-stage cervical cancer: Can it reliably guide lymph node management?” Gynecologic oncology (2026). PMID: 42224889 ↗
L3RETROSPECTIVE_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[56]
Frühauf F, Fischerová D, Moro F et al.. “Prospective comparison of diagnostic accuracy of ultrasound, PET/CT and DW-MRI for preoperative assessment of pelvic lymph nodes in cervical cancer patients: results of the CANNES trial.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2026). PMID: 42178785 ↗
L3COHORTCited in: Regional and Distant Metastatic Failure Patterns
[57]
Zhang L, Yang J, Zhang P et al.. “Association between log odds of positive lymph nodes and survival in surgically treated cervical cancer patients: a SEER database-based cohort study.” World journal of surgical oncology (2026). PMID: 41998619 ↗
L3COHORTCited in: Regional and Distant Metastatic Failure Patterns
[58]
Daix-Moreux M, El Hajj H, Schérier S et al.. “Para-aortic lymphadenectomy after negative PET-CT in locally advanced cervical cancer: a continuous monocentric series of 320 cases.” Gynecologic oncology (2026). PMID: 41719896 ↗
L4RETROSPECTIVE_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[59]
Bale CA, Pearce JV, Deng X et al.. “Prognostic value of FDG-PET SUV changes in cervical cancer following radiation therapy: a retrospective cohort study.” Archives of gynecology and obstetrics (2026). PMID: 41609820 ↗
L3RETROSPECTIVE_COHORTCited in: Regional and Distant Metastatic Failure Patterns
[60]
da Silva PHCM, Molino GOG, Dias MMF et al.. “Adjuvant Radiotherapy for Intermediate-Risk Early-Stage Cervical Cancer Post Radical Hysterectomy: A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2025). PMID: 40507766 ↗
L1SR_MA_RCTCited in: Risk Factors and Predictors of Recurrence
[61]
Yokoi A, Machida H, Okazawa-Sakai M et al.. “Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 42012622 ↗
L2SR_COHORTCited in: Risk Factors and Predictors of Recurrence
[62]
Zhao L, Zhai Q, Zhang W et al.. “Favorable short-term survival in locally advanced cervical cancer with optimal pathological response after neoadjuvant chemoimmunotherapy: a real-world analysis.” Frontiers in immunology (2026). PMID: 42023238 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[63]
Bae J, Kim U, Paik ES et al.. “Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria.” Gynecologic oncology (2025). PMID: 40311526 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[64]
Ng ZY, Manchanda R, Lopez A et al.. “The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.” Gynecologic oncology (2024). PMID: 39378742 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[65]
Guo Y, Liu Y, He Y et al.. “HPV viral load predicts immune exhaustion and prognosis in cervical neoplasia.” Frontiers in immunology (2026). PMID: 42440646 ↗
L3RETROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[66]
Tan L, Li H, Liu T et al.. “Perineural Invasion in Early-Stage Cervical Cancer: Marker of Aggressive Pathology and Increased Recurrence Risk.” Biomedicines (2026). PMID: 41898238 ↗
L3RETROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[67]
Espías-Alonso M, Gorostidi M, Zapardiel I et al.. “Assessment of ESGO Quality Indicators and Factors Associated with Recurrence Following Surgery for Early-Stage Cervical Cancer: A Retrospective Cohort Study.” Journal of clinical medicine (2025). PMID: 41096121 ↗
L3RETROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[68]
Bonatti M, Valletta R, D'Erme L et al.. “Preoperative staging of cervical cancer: time to shift from cystoscopy to MRI.” European radiology (2025). PMID: 41045303 ↗
L3COHORTCited in: Risk Factors and Predictors of Recurrence
[69]
Parulekar M, Kim MK, Noh JJ et al.. “Clinicopathological Factors Affecting Prognosis in Patients with Advanced Cervical Cancer Undergoing Concurrent Chemoradiation Therapy.” Cancers (2025). PMID: 41008885 ↗
L3COHORTCited in: Risk Factors and Predictors of Recurrence
[70]
Yin Z, Feng T, Xu Q et al.. “Monitoring circulating cell-free HPV DNA in metastatic or recurrent cervical cancer: clinical significance and treatment implications.” eLife (2025). PMID: 40960177 ↗
L3COHORTCited in: Risk Factors and Predictors of Recurrence
[71]
Xi Y, Zhou F, Liu Y et al.. “Clinical and pathological analyses of gastric-type cervical adenocarcinoma and its prognostic relevance.” Therapeutic advances in medical oncology (2025). PMID: 40755833 ↗
L3COHORTCited in: Risk Factors and Predictors of Recurrence
[72]
Aşıcıoğlu O, Ateş S, Varol F et al.. “Oncologic outcome and recurrence patterns of clinical stage IB and IIA cervical cancer: A large retrospective analysis of a tertiary reference center.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2025). PMID: 40662455 ↗
L3RETROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[73]
Olthof EP, Wenzel HHB, van der Velden J et al.. “Adjuvant Chemoradiotherapy or Radiotherapy Alone for Early Squamous Cervical Cancer with a Single Surgical-Pathological High-Risk Factor.” Cancers (2025). PMID: 40563690 ↗
L3COHORTCited in: Risk Factors and Predictors of Recurrence, Surgical Salvage Strategies for Local and Regional Recurrence
[74]
Huang KC, Cheng JY, Chen CS et al.. “The Prognostic Role of Magnetic-Resonance-Imaging-Detected Corpus Invasion in Patients with Cervical Carcinoma Who Underwent Definitive or Adjuvant Pelvic Radiotherapy.” Cancers (2025). PMID: 40361376 ↗
L3COHORTCited in: Risk Factors and Predictors of Recurrence
[75]
Li Y, Zhao J, Ding X et al.. “Oncologic Outcomes of Laparoscopic Radical Hysterectomy Incorporating Modified Tumor-Free Techniques.” Obstetrics and gynecology (2024). PMID: 39700500 ↗
L3RETROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[76]
Matsuo K, Shimada M, Matsuzaki S et al.. “Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024). PMID: 39107048 ↗
L3RETROSPECTIVE_COHORTCited in: Risk Factors and Predictors of Recurrence
[77]
Dhesi SS, Frood R, Swift S et al.. “Prediction of Patient Outcomes in Locally Advanced Cervical Carcinoma Following Chemoradiotherapy-Comparative Effectiveness of Magnetic Resonance Imaging and 2-Deoxy-2-[18F]fluoro-D-glucose Imaging.” Cancers (2024). PMID: 38339229 ↗
L4COHORTCited in: Risk Factors and Predictors of Recurrence
[78]
Bruno M, Bizzarri N, Teodorico E et al.. “The potential role of systemic inflammatory markers in predicting recurrence in early-stage cervical cancer.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2023). PMID: 38056022 ↗
L3COHORTCited in: Risk Factors and Predictors of Recurrence
[79]
Elit L, Fyles AW, Devries MC et al.. “Follow-up for women after treatment for cervical cancer: a systematic review.” Gynecologic oncology (2009). PMID: 19560188 ↗
L2SR_COHORTCited in: Imaging Surveillance and Early Detection of Recurrence
[80]
Luo J, Lin Y, Yi Q et al.. “Efficacy of focused ultrasound for HPV clearance and cervical LSIL treatment: a meta-analysis.” Scientific reports (2026). PMID: 41904252 ↗
L1SR_MA_RCTCited in: Imaging Surveillance and Early Detection of Recurrence
[81]
Bizzarri N, Querleu D, Ramirez PT et al.. “Minimally invasive simple hysterectomy in low-risk cervical cancer: a single-arm trial with stopping rules (ENGOT-cx23/MITO/LASH trial).” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2025). PMID: 40328196 ↗
L2NON_RANDOMIZED_TRIALCited in: Imaging Surveillance and Early Detection of Recurrence
[82]
Wang R, Luo H, Cao W. “Clinical and ultrasound features of uterine perivascular epithelioid cell tumors: case series and literature review.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 39395194 ↗
L4RETROSPECTIVE_COHORTCited in: Imaging Surveillance and Early Detection of Recurrence
[83]
Alcazar JL, Arribas S, Martinez-Monge R et al.. “Three-Dimensional Power Doppler Ultrasound for Predicting Response and Local Recurrence After Concomitant Chemoradiation Therapy for Locally Advanced Carcinoma of the Cervix.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2016). PMID: 26745701 ↗
L3COHORTCited in: Imaging Surveillance and Early Detection of Recurrence
[84]
Sartori E, Pasinetti B, Carrara L et al.. “Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.” Gynecologic oncology (2007). PMID: 17826824 ↗
L3COHORTCited in: Imaging Surveillance and Early Detection of Recurrence
[85]
Tan R, Xiao L, Sun J et al.. “A retrospective study of focused ultrasound versus cryotherapy in treatment of cervical squamous intraepithelial lesions.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2022). PMID: 36191925 ↗
L3COHORTCited in: Imaging Surveillance and Early Detection of Recurrence
[86]
Okuma K, Murakami N, Inaba K et al.. “Gel spacer-assisted salvage brachytherapy for pelvic recurrence after definitive chemoradiotherapy in cervical cancer: A single-institution retrospective study.” Brachytherapy (2025). PMID: 40769797 ↗
L4COHORTCited in: Imaging Surveillance and Early Detection of Recurrence
[87]
Gil-Ibañez B, Carreras-Dieguez N, López G et al.. “A multimodal intervention program to improve sexual health and self-perceived quality of life in patients treated for cervical cancer: a randomized prospective study (PROVIDENCE trial).” Journal of gynecologic oncology (2025). PMID: 39924671 ↗
L5STUDY_PROTOCOLCited in: Imaging Surveillance and Early Detection of Recurrence
[88]
Slama J, Fischerova D, Zikan M et al.. “Sensitivity of Follow-Up Methods in Patients After Fertility-Sparing Surgery for Cervical Cancers.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2017). PMID: 27668393 ↗
L5OTHERCited in: Imaging Surveillance and Early Detection of Recurrence
[89]
Wang Y, Tian S, Han X et al.. “Case Report: Misdiagnosis of cellular cervical adenomyoma.” Frontiers in oncology (2025). PMID: 41114377 ↗
L4CASE_SERIESCited in: Imaging Surveillance and Early Detection of Recurrence
[90]
Paris I, Prelaj A, Onesti CE et al.. “Esophageal stenosis: a differential diagnosis between esophageal cancer and metastasis from other neoplasia.” Anticancer research (2014). PMID: 24403488 ↗
L4CASE_SERIESCited in: Imaging Surveillance and Early Detection of Recurrence
[91]
Zhao X, Liu Y, Niu J et al.. “A phase III randomized clinical trial comparing laparoscopic radical hysterectomy based on open state with abdominal radical hysterectomy in patients with early-stage cervical cancer.” Trials (2024). PMID: 38992720 ↗
L5STUDY_PROTOCOLCited in: Imaging Surveillance and Early Detection of Recurrence
[92]
Höckel M, Wolf B, Schmidt K et al.. “Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.” The Lancet. Oncology (2019). PMID: 31383547 ↗
L4PROSPECTIVE_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[93]
Höckel M, Horn LC, Manthey N et al.. “Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis.” The Lancet. Oncology (2009). PMID: 19482513 ↗
L2NON_RANDOMIZED_TRIALCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[94]
Braungart S, Davenport R. “Clear Cell Adenocarcinoma of the Uterine Cervix and Vagina in Children Without Exposure to Diethylstilbestrol.” Pediatric blood & cancer (2025). PMID: 40369788 ↗
L4SR_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[95]
Leitao MM, Kreaden US, Laudone V et al.. “The RECOURSE Study: Long-term Oncologic Outcomes Associated With Robotically Assisted Minimally Invasive Procedures for Endometrial, Cervical, Colorectal, Lung, or Prostate Cancer: A Systematic Review and Meta-analysis.” Annals of surgery (2022). PMID: 36073772 ↗
L2SR_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[96]
Huang H, Li X, Xu Q et al.. “Impact of regional lymph node surgery and lymph node status on survival of small cell cervical cancer patients undergoing primary site surgery.” International journal of surgery (London, England) (2025). PMID: 41208591 ↗
L2PROSPECTIVE_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[97]
Lin W, Yao B, He J et al.. “The effect of physical therapy and mechanical stimulation on dysfunction of lower extremities after total pelvic exenteration in cervical carcinoma patient with rectovesicovaginal fistula induced by radiotherapy: a case report.” Journal of medical case reports (2024). PMID: 38610054 ↗
L1RCTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[98]
Conte C, Della Corte L, Pelligra S et al.. “Assessment of Salvage Surgery in Persistent Cervical Cancer after Definitive Radiochemotherapy: A Systematic Review.” Medicina (Kaunas, Lithuania) (2023). PMID: 36837394 ↗
L2SR_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[99]
Maeda M, Hisa T, Kurahashi H et al.. “Surgical Management for Transposed Ovarian Recurrence of Cervical Cancer: A Systematic Review with Our Experience.” Current oncology (Toronto, Ont.) (2022). PMID: 36290840 ↗
L4SR_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[100]
Adachi H, Ito H, Nagashima T et al.. “Prognostic Impact of Pulmonary Metastasectomy for Uterine Malignancies: A Retrospective Analysis of 38 Cases.” Cancers (2025). PMID: 41514526 ↗
L4COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[101]
Wolf B, Trantaki DS, Horn LC et al.. “Preoperative conization in cervical cancer patients undergoing open abdominal radical hysterectomy: Results from a propensity-score matched study.” Gynecologic oncology (2025). PMID: 40179519 ↗
L3COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[102]
Howlett LN, Fadadu PP, Grcevich LO et al.. “Intraoperative Radiation Therapy for Recurrent Cervical and Endometrial Cancer: Predicting Morbidity and Mortality in a Contemporary Cohort.” Cancers (2024). PMID: 39518067 ↗
L4RETROSPECTIVE_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[103]
Scherer-Quenzer AC, Findeis J, Herbert SL et al.. “The value of endocervical curettage during large loop excision of the transformation zone in combination with endocervical surgical margin in predicting persistent/recurrent dysplasia of the uterine cervix: a retrospective study.” BMC women's health (2024). PMID: 39169335 ↗
L3COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[104]
Falconer H, Norberg-Hardie A, Salehi S et al.. “Oncologic outcomes after Total Mesometrial Resection (TMMR) or treatment according to current international guidelines in FIGO (2009) stages IB1-IIB cervical cancer: an observational cohort study.” EClinicalMedicine (2024). PMID: 39007068 ↗
L3COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[105]
Choi KH, Lee HC, Kim YS et al.. “Diagnostic assessments and treatment results of well-differentiated gastric-type adenocarcinoma of the uterine cervix (Adenoma malignum): A multicenter retrospective analysis of KROG 22-03 study.” Gynecologic oncology (2024). PMID: 38246046 ↗
L4COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[106]
Kita M, Butsuhara Y, Hisamatsu Y et al.. “Pneumovaginoscopy-assisted radical hysterectomy for early-stage cervical cancer: a novel bidirectional approach for tumor spillage prevention and R0 resection.” Journal of gynecologic oncology (2023). PMID: 37477103 ↗
L4RETROSPECTIVE_COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[107]
Zhong Q, Tang F, Ni T et al.. “Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy.” Frontiers in immunology (2022). PMID: 36325337 ↗
L3COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence, Re‑irradiation and Advanced Radiation Techniques for Recurrence
[108]
Cho WK, Kim HS, Park W et al.. “Predicting prognosis according to the updated WHO classification in patients with endocervical adenocarcinoma treated with surgery and radiotherapy.” Journal of gynecologic oncology (2022). PMID: 36047374 ↗
L3COHORTCited in: Surgical Salvage Strategies for Local and Regional Recurrence
[109]
Kamrava M, Leung E, Bachand F et al.. “GEC-ESTRO (ACROP)-ABS-CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina.” International journal of radiation oncology, biology, physics (2022). PMID: 36191741 ↗
L1GUIDELINECited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[110]
Vieira-Serna S, Viveros-Carreño D, Rodríguez J et al.. “Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.” Gynecologic oncology (2022). PMID: 36459858 ↗
L1SR_MA_RCTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[111]
Kang HB, Kim SH, Lee JH et al.. “MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial.” International journal of clinical oncology (2024). PMID: 38530569 ↗
L2NON_RANDOMIZED_TRIALCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[112]
Lee HC, Jeong JW, Lee JH et al.. “High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.” Gynecologic oncology (2023). PMID: 37689018 ↗
L2NON_RANDOMIZED_TRIALCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[113]
Parikh S, Zhang Y, Sherwani Z et al.. “Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review.” Brachytherapy (2024). PMID: 38307787 ↗
L2SR_COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[114]
Barcellini A, Vai A, Fontana G et al.. “Particle Beam Re-irradiation in Oligo Recurrent Gynecological Malignancies.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2026). PMID: 41830666 ↗
L4RETROSPECTIVE_COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[115]
Fujioka D, Saito T, Sumiya T et al.. “Salvage Interstitial Brachytherapy for Isolated Local Recurrence of Cervical and Endometrial Cancer: A Retrospective Analysis Stratified by Type of Pelvic Irradiation History.” Cancers (2026). PMID: 41595173 ↗
L3COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[116]
Sittiwong W, Prasartseree T, Tuntapakul P et al.. “Re-irradiation in oligorecurrence and oligometastatic cervical cancer in modern radiotherapy era.” Radiation oncology (London, England) (2025). PMID: 41225583 ↗
L3COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[117]
Sapienza LG, Chapman CH, Jhavar S et al.. “Understanding Hydronephrosis Occurrence by an Individual-Kidney Level Analysis of all Events Postchemoradiation Therapy for Locally Advanced Cervical Cancer.” International journal of radiation oncology, biology, physics (2025). PMID: 40348198 ↗
L3COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[118]
Choi YK, Lee JH, Kim YS et al.. “Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.” Gynecologic oncology (2024). PMID: 39241617 ↗
L3COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[119]
Gao H, Wu H, Zhang Y et al.. “Long-term survival in patients with para-aortic metastatic cervical cancer receiving simultaneous integrated boost chemoradiation to positive lymph nodes: a single-center experience.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024). PMID: 39209431 ↗
L4RETROSPECTIVE_COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[120]
Chuk E, Yu C, Scott AA et al.. “Clinical Outcomes of 3 Versus 4 Fractions of Magnetic Resonance Image-Guided Brachytherapy in Cervical Cancer.” International journal of radiation oncology, biology, physics (2024). PMID: 38936633 ↗
L3COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[121]
Ouma GE, Asaso Omwodo K, Itsura P et al.. “Characterizing trimodal therapy outcomes by HIV status in early-stage cervical cancer: a retrospective cohort study from a Kenyan tertiary centre.” BMC cancer (2026). PMID: 41796282 ↗
L2PROSPECTIVE_COHORTCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[122]
Wu M, Jiang Z, Xian X et al.. “Transrectal ultrasound-guided optimization of needle insertion for interstitial brachytherapy in the treatment of vaginal stump recurrence of cervical cancer.” BMC cancer (2026). PMID: 41794657 ↗
L2NON_RANDOMIZED_TRIALCited in: Re‑irradiation and Advanced Radiation Techniques for Recurrence
[123]
Abu-Rustum NR, Yashar CM, Arend R et al.. “NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38081139 ↗
L1GUIDELINECited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[124]
Abu-Rustum NR, Yashar CM, Bean S et al.. “NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32502976 ↗
L1GUIDELINECited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[125]
Lu YC, Parker LL, Lu T et al.. “Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28809608 ↗
L2NON_RANDOMIZED_TRIALCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[126]
Lan C, Shen J, Wang Y et al.. “Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 33052760 ↗
L2NON_RANDOMIZED_TRIALCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[127]
Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗
L5NARRATIVE_REVIEWCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[128]
Koh WJ, Greer BE, Abu-Rustum NR et al.. “Cervical Cancer, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25870376 ↗
L5OTHERCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[129]
Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗
L4PHASE_1_TRIALCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[130]
Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗
L1SR_MA_RCTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[131]
Yarza R, Kountouri M, Guedes H et al.. “Progression-free survival as a potential surrogate end point for overall survival in advanced cervical carcinoma.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024). PMID: 39971452 ↗
L1SR_MA_RCTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[132]
Stevanović S, Helman SR, Wunderlich JR et al.. “A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30518633 ↗
L2NON_RANDOMIZED_TRIALCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[133]
Kang Z, Stevanović S, Hinrichs CS et al.. “Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899967 ↗
L4COHORTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[134]
Lan LF, Chen YJ, Mo DC et al.. “Comparative effectiveness of immune checkpoint inhibitors in squamous vs. non-squamous cervical carcinoma: a systematic review and meta-analysis of randomized controlled trials.” Translational cancer research (2026). PMID: 42445390 ↗
L1SR_MA_RCTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[135]
Li H, Xu Y, Jiao X et al.. “IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.” Med (New York, N.Y.) (2025). PMID: 39827881 ↗
L2RCT_PHASE2Cited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[136]
Danisch M, Postl M, Bartl T et al.. “Novel Treatment Concepts for Cervical Cancer-Moving Towards Personalized Therapy.” Journal of personalized medicine (2025). PMID: 41295223 ↗
L1RCTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[137]
Qian-Zhang S, Romero-Triana D, Meliga C et al.. “Pancreatic Metastases from Cervical Squamous Cell Carcinoma: Systematic Review of the Literature and Case Report.” Biomedicines (2025). PMID: 41301806 ↗
L2SR_COHORTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[138]
Saad A, Taylor A, Felder S et al.. “De-escalating first-line treatment in stage IVB or recurrent cervical cancer: outcomes of immunotherapy alone and systemic review.” The oncologist (2025). PMID: 40421960 ↗
L2SR_COHORTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[139]
Balan L, Cimpean AM, Nandarge PS et al.. “Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis.” Biomedicines (2024). PMID: 38791070 ↗
L2SR_COHORTCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[140]
Kibudde S, Kavuma A, Abal B et al.. “Radiation therapy for cervical cancer in Uganda: a practice guideline.” Ecancermedicalscience (2025). PMID: 41561518 ↗
L1GUIDELINECited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[141]
Attademo L, Tuninetti V, Pisano C et al.. “Immunotherapy in cervix cancer.” Cancer treatment reviews (2020). PMID: 32827839 ↗
L5NARRATIVE_REVIEWCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[142]
Monk BJ, Enomoto T, Kast WM et al.. “Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.” Cancer treatment reviews (2022). PMID: 35413489 ↗
L5NARRATIVE_REVIEWCited in: Systemic and Immunotherapeutic Options for Metastatic Recurrence
[143]
Gray HJ. “Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267058 ↗
L1RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[144]
. “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗
L1SR_MA_RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[145]
Ryu SY, Deng W, Albuquerque K et al.. “Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40947016 ↗
L1RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[146]
Sugiyama T, Fujiwara K, Ohashi Y et al.. “Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24569914 ↗
L1RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[147]
Moore DH. “Chemotherapy for advanced, recurrent, and metastatic cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267059 ↗
L2NON_RANDOMIZED_TRIALCited in: Prognosis and Long‑Term Outcomes After Recurrence
[148]
Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗
L3COHORTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[149]
Ramirez PT, Robledo KP, Frumovitz M et al.. “LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38810208 ↗
L1RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[150]
Lai CH, Chang CJ, Huang HJ et al.. “Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17704412 ↗
L3COHORTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[151]
Uppal S, Gehrig PA, Peng K et al.. “Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32031867 ↗
L3RETROSPECTIVE_COHORTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[152]
Ryu SY, Nam BH, Kim MH et al.. “A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.” ESMO open (2026). PMID: 41812622 ↗
L1RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[153]
Frumovitz M, Obermair A, Coleman RL et al.. “Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 32502445 ↗
L1RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[154]
Ramirez PT, Frumovitz M, Pareja R et al.. “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.” The New England journal of medicine (2018). PMID: 30380365 ↗
L1RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[155]
da Costa SCS, Bonadio RC, Gabrielli FCG et al.. “Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31449470 ↗
L2RCT_PHASE2Cited in: Prognosis and Long‑Term Outcomes After Recurrence
[156]
Xiao C, Zeng S, Li L et al.. “Efficacy and safety of immune checkpoint inhibitors combined with chemoradiotherapy in locally advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 41859340 ↗
L1SR_MA_RCTCited in: Prognosis and Long‑Term Outcomes After Recurrence
[157]
Morice P, Scambia G, Abu-Rustum NR et al.. “Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE.” The Lancet. Oncology (2024). PMID: 39216500 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[158]
Fontham ETH, Wolf AMD, Church TR et al.. “Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.” CA: a cancer journal for clinicians (2020). PMID: 32729638 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[159]
Amant F, Planchamp F, Berveiller P et al.. “ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2025). PMID: 40707270 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[160]
Perkins RB, Wolf AMD, Church TR et al.. “Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline.” CA: a cancer journal for clinicians (2026). PMID: 41342729 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[161]
Disis ML, Adams SF, Bajpai J et al.. “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.” Journal for immunotherapy of cancer (2023). PMID: 37295818 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[162]
Kilcoyne A, Gottumukkala RV, Kang SK et al.. “ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer.” Journal of the American College of Radiology : JACR (2021). PMID: 34794599 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[163]
Gori S, Venturelli F, Carozzi F et al.. “Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology.” British journal of cancer (2025). PMID: 40931128 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[164]
Cibula D, Pötter R, Planchamp F et al.. “The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2018). PMID: 29688967 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[165]
Croke J, Fyles A, Barbera L et al.. “Radiation therapy quality-of-care indicators for locally advanced cervical cancer: A consensus guideline.” Practical radiation oncology (2016). PMID: 27596034 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[166]
Massad LS, Einstein MH, Huh WK et al.. “2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.” Obstetrics and gynecology (2013). PMID: 23635684 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[167]
Cibula D, Pötter R, Planchamp F et al.. “The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2018). PMID: 29728273 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[168]
Cibula D, Pötter R, Planchamp F et al.. “The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer.” Virchows Archiv : an international journal of pathology (2018). PMID: 29725757 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[169]
Shinagare AB, Burk KS, Kilcoyne A et al.. “ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix: 2023 Update.” Journal of the American College of Radiology : JACR (2024). PMID: 38823948 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[170]
Hamel C, Avard B, Lim H et al.. “Canadian Association of Radiologists Cancer Diagnostic Imaging Referral Guideline.” Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes (2025). PMID: 39843994 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[171]
Saslow D, Solomon D, Lawson HW et al.. “American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.” American journal of clinical pathology (2012). PMID: 22431528 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[172]
Saslow D, Solomon D, Lawson HW et al.. “American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.” CA: a cancer journal for clinicians (2012). PMID: 22422631 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[173]
Reid E, Suneja G, Ambinder RF et al.. “AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787130 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[174]
Laporte GA, Zanini LAG, Zanvettor PH et al.. “Guidelines of the Brazilian Society of Oncologic Surgery for pelvic exenteration in the treatment of cervical cancer.” Journal of surgical oncology (2019). PMID: 31777095 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[175]
Wolfson AH, Varia MA, Moore D et al.. “ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer.” Gynecologic oncology (2011). PMID: 22155418 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations
[176]
Cibula D, Mburu A, Planchamp F et al.. “European Society of Gynaecological Oncology resource-stratified guidelines for the management of patients with cervical cancer.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2025). PMID: 41494219 ↗
L1GUIDELINECited in: Guidelines, Surveillance Protocols, and Follow‑Up Recommendations